Retrospective analysis of type 2 diabetes prevalence in a systemic sclerosis cohort from southern Italy: Comment on “Reduced incidence of Type 1 diabetes and Type 2 diabetes in systemic sclerosis: A nationwide cohort study” by Tseng et al., Joint Bone Spine 2016;83:307–13

2016 ◽  
Vol 83 (5) ◽  
pp. 611-612 ◽  
Author(s):  
Francesco Ursini ◽  
Salvatore D’Angelo ◽  
Angela Padula ◽  
Michele Gilio ◽  
Emilio Russo ◽  
...  
2016 ◽  
Vol 83 (3) ◽  
pp. 307-313 ◽  
Author(s):  
Chia-Chun Tseng ◽  
Shun-Jen Chang ◽  
Wen-Chan Tsai ◽  
Tsan-Teng Ou ◽  
Cheng-Chin Wu ◽  
...  

2016 ◽  
Vol 83 (5) ◽  
pp. 613
Author(s):  
Chia-Chun Tseng ◽  
Shun-Jen Chang ◽  
Wen-Chan Tsai ◽  
Tsan-Teng Ou ◽  
Cheng-Chin Wu ◽  
...  

Cephalalgia ◽  
2017 ◽  
Vol 38 (11) ◽  
pp. 1759-1764 ◽  
Author(s):  
Ippazio Cosimo Antonazzo ◽  
Trond Riise ◽  
Marianna Cortese ◽  
Line Iden Berge ◽  
Anders Engeland ◽  
...  

Background Results from studies on diabetes and migraine risk are conflicting, which may be due to methodological limitations. Prospective studies with long follow-up could increase our understanding of the relationship between the two diseases. Method We performed a cohort study including the whole Norwegian population alive on 01.01.2004, using prescriptions registered in the Norwegian prescription database to identify individuals developing type 1 diabetes, type 2 diabetes and migraine during follow-up (10 years). We used Cox proportional hazards regression to estimate rate ratios with corresponding 95% confidence intervals for the effect of diabetes on migraine risk, adjusting for age, sex, and educational level. Result We identified 7,883 type 1 diabetes patients and 93,600 type 2 patients during the study period. Type 1 diabetes was significantly associated with a subsequent decreased migraine risk during follow-up in the age- and sex-adjusted analyses (0.74; 0.61–0.89). Type 2 diabetes was also associated with a significantly lower migraine risk (0.89; 0.83–0.95). Further adjustment for educational level yielded similar results for both diabetes. Conclusion Both type 1 and type 2 diabetes were significantly associated with a decreased risk of migraine. This suggests that diabetes or diabetes treatment may have a protective effect on the development of migraine.


Diabetologia ◽  
2020 ◽  
Vol 63 (9) ◽  
pp. 1736-1744
Author(s):  
Michael Due Larsen ◽  
Dorte Møller Jensen ◽  
Jens Fedder ◽  
Line Riis Jølving ◽  
Bente Mertz Nørgård

Diabetologia ◽  
2020 ◽  
Vol 63 (10) ◽  
pp. 2123-2128 ◽  
Author(s):  
Anna-Maaria Auvinen ◽  
Kaisu Luiro ◽  
Jari Jokelainen ◽  
Ilkka Järvelä ◽  
Mikael Knip ◽  
...  

Abstract Aims/hypothesis The aim of this work was to examine the progression to type 1 and type 2 diabetes after gestational diabetes mellitus (GDM) in a 23 year follow-up study. Methods We carried out a cohort study of 391 women with GDM diagnosed by an OGTT or the use of insulin treatment during pregnancy, and 391 age- and parity-matched control participants, who delivered in 1984–1994 at the Oulu University Hospital, Finland. Diagnostic cut-off levels for glucose were as follows: fasting, ≥4.8 mmol/l; 1 h, ≥10.0 mmol/l; and 2 h, ≥8.7 mmol/l. Two follow-up questionnaires were sent (in 1995–1996 and 2012–2013) to assess the progression to type 1 and type 2 diabetes. Mean follow-up time was 23.1 (range 18.7–28.8) years. Results Type 1 diabetes developed (5.7%) during the first 7 years after GDM pregnancy and was predictable at a 2 h OGTT value of 11.9 mmol/l during pregnancy (receiver operating characteristic analysis: AUC 0.91, sensitivity 76.5%, specificity 96.0%). Type 2 diabetes increased linearly to 50.4% by the end of the follow-up period and was moderately predictable with fasting glucose (AUC 0.69, sensitivity 63.5%, specificity 68.2%) at a level of 5.1 mmol/l (identical to the fasting glucose cut-off recommended by the International Association of Diabetes and Pregnancy Study Groups [IADPSG) and WHO]). Conclusions/interpretation All women with GDM should be intensively monitored for a decade, after which the risk for type 1 diabetes is minimal. However, the incidence of type 2 diabetes remains linear, and therefore individualised lifelong follow-up is recommended.


2021 ◽  
Author(s):  
Caren Sourij ◽  
Norbert Joachim Tripolt ◽  
Faisal Aziz ◽  
Felix Aberer ◽  
Patrick Forstner ◽  
...  

Aims: Immune response to COVID-19 vaccination and a potential impact of glycaemia on antibody levels in people with diabetes remains unclear. We investigated the seroconversion following first and second COVID-19 vaccination in people with type 1 and type 2 diabetes in relation to glycaemic control prior to vaccination and analysed the response in comparison to individuals without diabetes. Materials and Methods: This prospective, multicenter cohort study analysed people with type 1 and type 2 diabetes, well (HbA1c<7.5% or <58 mmol/mol) or insufficiently (HbA1c≥7.5% or ≥58 mmol/mol) controlled and healthy controls. Roche's Elecsys anti-SARS-CoV-2 S was used to quantify anti-spike protein antibodies 7-14 days after the first and 14-21 days after the second vaccination. Results: 86 healthy controls and 161 participants with diabetes were enrolled, 150 (75 with type 1 diabetes and 75 with type 2 diabetes) were eligible for the analysis. After the first vaccination, only 52.7% in the type 1 diabetes group and 48.0% in the type 2 diabetes group showed antibody levels above the cut-off for positivity. Antibody levels after the second vaccination were similar in people with type1, type 2 diabetes and healthy controls if adjusted for age, sex and multiple testing (p>0.05). Age (r=-0.45, p<0.001) and glomerular filtration rate (r=0.28, p=0.001) were significantly associated with antibody response. Conclusions: Anti-SARS-CoV-2 S antibody levels after the second vaccination were comparable in healthy controls, people with type 1 and type 2 diabetes, irrespective of glycaemic control. Age and renal function correlated significantly with the extent of antibody levels.


2017 ◽  
Author(s):  
Marwa Omri ◽  
Rayene Ben Mohamed ◽  
Imen Rezgani ◽  
Sana Mhidhi ◽  
Aroua Temessek ◽  
...  

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1746-P
Author(s):  
PATTARA WIROMRAT ◽  
MELANIE CREE-GREEN ◽  
BRYAN C. BERGMAN ◽  
KALIE L. TOMMERDAHL ◽  
AMY BAUMGARTNER ◽  
...  

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1264-P
Author(s):  
FABRIZIO BARBETTI ◽  
RICCARDO BONFANTI ◽  
MAURIZIO DELVECCHIO ◽  
DARIO IAFUSCO ◽  

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 110-OR
Author(s):  
MARIA J. REDONDO ◽  
MEGAN V. WARNOCK ◽  
LAURA E. BOCCHINO ◽  
SUSAN GEYER ◽  
ALBERTO PUGLIESE ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document